WHO
World Health Organization
Topic A: Cross Border Flows of Unapproved and Off-Patent Medicines
Medicines are an important part of keeping everyone healthy, but not everyone in the world has equal access to them. Medicines often flow across national borders so that countries can receive the treatments needed. However, countries have different regulations about which medicines are safe and appropriate for use. An unapproved medicine is a medicine that has not been officially accepted for use by a country’s health board. An off patent medicine is a medicine whose patent has expired, meaning other companies can legally make and sell their own versions of it at a lower price. The movement of these drugs across borders has benefits and risks. Off patent medicines make life saving treatments more accessible, especially in countries with limited healthcare resources. Still medicines that have not been authorized in a country may not have been properly tested for safety, quality, and effectiveness. Illegal and poorly regulated medicine shipments can lead to unsafe products reaching patients. Delegates must consider how countries can make drugs more accessible while also protecting consumers from unsafe products.
Topic B: Patents, Licensing, and Access to Medicines for Chronic Diseases
Chronic diseases often require long term treatment. Although several effective medicines exist, patients in some countries deal with expensive prices, limited supply, and a lack of access to the medicines they need. Patents and licensing play an important role in deciding how drugs are produced, priced, and distributed. Pharmaceutical companies argue that strong patent protections are needed because developing new medicines demands significant time and money. So to incentivize companies to continue supplying medicines and creating new ones, patents are implemented. At the same time governments and health organizations must consider whether patents and medicine prices limit patients from receiving essential treatments. Licensing agreements allow additional manufacturers to produce medicines, increasing the supply and lowering costs. WHO must consider how the international community can improve access to medicines for chronic diseases while still encouraging medicinal research and innovation.